Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

518
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
518
Glaucoma: Overview01:25

Glaucoma: Overview

674
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
674
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

608
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
608

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparison of temporal versus nasal positioning of iStent Inject W®.

Journal francais d'ophtalmologie·2026
Same author

Orbital exenteration 14years after evisceration for misdiagnosed choroidal melanoma.

Journal francais d'ophtalmologie·2026
Same author

Proliferative vitreoretinopathy-induced central retinal artery occlusion.

Journal francais d'ophtalmologie·2026
Same author

Etiologies of intermediate uveitis in a tertiary center: an age-oriented medical assessment?

Journal of ophthalmic inflammation and infection·2025
Same author

A new anti-outer plexiform layer antibody in autoimmune retinopathy?

Journal francais d'ophtalmologie·2025
Same author

The use of doxycycline in refractory idiopathic uveitis.

Journal francais d'ophtalmologie·2025

Related Experiment Video

Updated: Aug 14, 2025

Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis
10:33

Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis

Published on: December 17, 2021

2.8K

[Sarcoid uveitis: Ophthalmologist's and internist's viewpoints].

P Sève1, R Jacquot2, T El Jammal2

  • 1Service de médecine interne, Hospices civils de Lyon, Hôpital de la Croix-Rousse, 103, grande rue de la Croix-Rousse, 69317 Lyon cedex 04, France; Hospices civils de Lyon, Pôle IMER, 69003 Lyon, France; Université de Lyon, Lyon, France; University Lyon, University Claude Bernard-Lyon 1, HESPER EA 7425, 69008 Lyon, France.

La Revue De Medecine Interne
|January 15, 2023
PubMed
Summary

Sarcoidosis frequently causes inflammatory eye disease, primarily uveitis, which can lead to vision loss. Early diagnosis and advanced therapies like anti-TNF-α drugs improve visual prognosis for ocular sarcoidosis.

Keywords:
Anti TNF-αSarcoidosisSarcoïdoseUveitisUvéite

More Related Videos

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model
07:40

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model

Published on: January 12, 2022

5.0K
Iris Fixation via External Pentagram Suturing
05:22

Iris Fixation via External Pentagram Suturing

Published on: May 5, 2022

1.4K

Related Experiment Videos

Last Updated: Aug 14, 2025

Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis
10:33

Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis

Published on: December 17, 2021

2.8K
Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model
07:40

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model

Published on: January 12, 2022

5.0K
Iris Fixation via External Pentagram Suturing
05:22

Iris Fixation via External Pentagram Suturing

Published on: May 5, 2022

1.4K

Area of Science:

  • Ophthalmology
  • Rheumatology
  • Immunology

Context:

  • Sarcoidosis is a multisystem inflammatory disease.
  • Ocular involvement is common, with uveitis being the most frequent manifestation.
  • Ocular sarcoidosis can lead to significant vision impairment.

Purpose:

  • To review the clinical presentation, diagnosis, and management of ocular sarcoidosis.
  • To highlight the impact of cystoid macular edema on visual prognosis.
  • To discuss current and emerging therapeutic strategies.

Summary:

  • Ocular sarcoidosis commonly presents as uveitis, characterized by specific clinical signs like mutton-fat keratic precipitates and iris nodules.
  • Posterior segment involvement includes vitritis, vasculitis, and choroidal lesions, with cystoid macular edema being a major sight-threatening complication.
  • While corticosteroids are primary treatment, steroid-sparing agents and biologics, particularly anti-TNF-α therapies, are crucial for refractory cases.

Impact:

  • Early detection and multimodal treatment strategies have improved visual outcomes in ocular sarcoidosis.
  • Advances in therapy, including systemic immunosuppressants and biologics, offer effective management options for challenging cases.
  • Understanding the disease spectrum and treatment landscape is vital for preserving vision in patients with sarcoid uveitis.